About 1 in 5 second-level appeals of denied anticancer medications in Medicare Part D were overturned, according to a study published July 23 in JAMA Network Open. Researchers analyzed 4,952 second-level appeals from 2020 to 2024.
Here are four things to know:
- Overall, 19.5% of appeals received favorable reviews, meaning a Medicare-contracted reviewer overturned the Part D plan’s initial denial.
- The reversal rate was highest for drugs initially denied for failing to meet prior authorization coverage criteria, which generally involved on-label prescribing. Among these appeals, 61.1% received favorable reviews.
- Most appeals involved drugs initially denied for non-medically accepted indications, or off-label use, accounting for 3,410 appeals, or 68.9% of the total. Of these, 16.5% received favorable reviews. Clerical issues were cited in 72.6% of unfavorable reviews in this category.
- The researchers said the findings suggest Part D plans may be making inappropriate utilization management decisions. They pointed to streamlining the preapproval process for on-label therapies as a potential improvement.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
